Drug data last refreshed 17h ago · AI intelligence enriched 4w ago
TIMENTIN is an injectable small-molecule antibiotic combination approved in 1985 for bacterial infections. The product is a fixed-combination formulation delivered via injection for systemic infection treatment. Generic alternatives are available in most markets.
As a legacy injectable antibiotic approaching loss of exclusivity, TIMENTIN operates in a commoditized market with moderate competitive pressure (30/100) and likely small, maintenance-focused commercial teams.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
TIMENTIN offers limited career growth opportunity given its LOE trajectory and minimal linked job openings. Roles on this product are typically maintenance-focused and best suited for professionals managing portfolio defense or seeking stable, lower-visibility positions.
Worked on TIMENTIN at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.